The efficacy of RGD modified liposomes loaded with vinorelbine plus tetrandrine in treating resistant brain glioma

Li, Xuetao; Tang, Wei; Xie, Hongjun; Liu, Shuang; Song, Xiaoli; Xiao, Yao; Wang, Xin; Cheng, Lan; Chen, Guirong

doi:10.1080/08982104.2017.1408649

Cited by 26 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limitation of this study is that it is not clear whether TetC can pass through the blood-brain barrier. It is reported that tetrandrine liposomes could pass through blood-brain barrier (39). If TetC cannot pass the blood-brain barrier, Tet liposomes will be used in a future study.…”

Section: Discussionmentioning

confidence: 99%

Antitumor activity of tetrandrine citrate in human glioma U87 cells in vitro and in vivo

et al. 2019

View full text Add to dashboard Cite

Since the current methods of treatment for malignant glioma, radiotherapy and chemotherapy, are unsatisfactory, the development of novel therapeutic compounds is required. In the present study, the inhibitory effect of tetrandrine citrate (TetC) on the proliferation of human glioma U87 cells, as well as its mechanism of action, were investigated. An MTT assay was used to assess cell viability in vitro, and the production of intracellular reactive oxygen species (ROS) was determined by assessing the fluorescence intensity of 2,7-dichlorofluorescein (DCF). Flow cytometry was used to determine the level of apoptosis and cell cycle status, and the protein expression levels of apoptosis-associated proteins were determined using western blotting. Additionally, the antitumor activity of TetC was assessed in vivo using a nude mouse xenograft model. The results revealed that in vitro, the proliferative rate of U87, U251 and human umbilical vein endothelial cells (HUVECs) was significantly reduced in a dose-dependent manner following treatment with TetC, although TetC had the greatest inhibitory effect on U87 cells. The vacuolization and apoptosis of U87 cells was induced using 10 and 20 µmol/l TetC, respectively. The overall proliferative inhibition was associated with an increase in the levels of ROS and apoptosis. In TetC-treated cells, the expression levels of apoptosis-related proteins, including cleaved (CL) caspase-3, Fas, phosphorylated (p)-p38 and p-JNK, were increased, whereas those of caspase-3 and Bcl-2 were decreased. In vivo, TetC was highly effective at inhibiting the growth of human glioma U87 xenografts in BALB/c nude mice, with a percentage growth inhibition of ≥68.7%. These findings indicated that the potent antitumor activity of TetC may be mediated through an increase in ROS levels, the downregulation of Bcl-2, and the upregulation of CL caspase-3, Fas, p-p38 and p-JNK expression levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Antitumor activity of tetrandrine citrate in human glioma U87 cells in vitro and in vivo

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Among all the different nanocarriers (Figure 1), liposomes have been largely used. Preclinical studies using liposomes loaded with doxorubicin or coated with temozolomide showed higher concentrations of these drugs inside the brain when compared with the plasmatic levels; in these same models, survival benefit was also described (Zhao et al, 2018;Li et al, 2019). Noteworthy, liposomal doxorubicin has been clinically used in primary and recurrent high-grade glioma patients, and good biodistribution and decent outcomes were obtained; however, none of the studies were randomized controlled trials (RCTs) and were published just before or after the publication of the Stupp protocol (Fabel et al, 2001;Hau et al, 2004).…”

Section: Nanoparticles As Nanocarriersmentioning

confidence: 92%

Nanoparticles for Stem Cell Therapy Bioengineering in Glioma

Ruiz‐Garcia

Alvarado-Estrada

Krishnan

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Gliomas are a dismal disease associated with poor survival and high morbidity. Current standard treatments have reached a therapeutic plateau even after combining maximal safe resection, radiation, and chemotherapy. In this setting, stem cells (SCs) have risen as a promising therapeutic armamentarium, given their intrinsic tumor homing as well as their natural or bioengineered antitumor properties. The interplay between stem cells and other therapeutic approaches such as nanoparticles holds the potential to synergize the advantages from the combined therapeutic strategies. Nanoparticles represent a broad spectrum of synthetic and natural biomaterials that have been proven effective in expanding diagnostic and therapeutic efforts, either used alone or in combination with immune, genetic, or cellular therapies. Stem cells have been bioengineered using these biomaterials to enhance their natural properties as well as to act as their vehicle when anticancer nanoparticles need to be delivered into the tumor microenvironment in a very precise manner. Here, we describe the recent developments of this new paradigm in the treatment of malignant gliomas.

show abstract

“…RPV‐modified epirubicin and dioscin co‐delivery liposomes were prepared using thin‐film hydration . Briefly, egg‐yolk phosphatidylcholine (EPC), cholesterol, DSPE‐PEG 2000 , DSPE‐PEG 2000 ‐RPV, and dioscin were dissolved in methyl alcohol at a molar ratio of 100:30:3:2:7 in a pear‐shaped bottle, and dried by rotary evaporator at 37°C to obtain a thin film.…”

Section: Methodsmentioning

confidence: 99%

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

et al. 2020

View full text Add to dashboard Cite

| 621 wileyonlinelibrary.com/journal/cas | INTRODUC TI ONLung cancer is one of the most common malignancies and a leading cause of cancer-related death worldwide. 1 Among all lung cancers, approximately 85% are non-small cell lung cancer (NSCLC), for which morbidity is significantly higher than for small cell lung cancer. 2 In the past decade, targeted therapy, immunotherapy, and similar approaches rapidly developed to become the new treatment modalities for NSCLC. Despite recent developments and improvements in diagnosis and treatment, prospects for patients with NSCLC are dismal and the 5-year overall survival rate is only 15%-18%. 3,4 Rapid growth and metastasis are basic biological characteristics of malignant tumors, including NSCLC. 5 It is well known that angiogenesis plays a key role in cancer growth and metastasis. Anti-angiogenesis treatment has evolved to achieve encouraging results, but despite the widespread application of anti-angiogenic drugs, they have not attained satisfactory efficacy. [6][7][8] This means that alternative nutrient supply channels support tumor growth.Vasculogenic mimicry (VM) is defined as formation of vascu- lar-like structures lined with tumor cells without the presenceThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractChemotherapy for non-small cell lung cancer (NSCLC) is far from satisfactory, mainly due to poor targeting of antitumor drugs and self-adaptations of the tumors.Angiogenesis, vasculogenic mimicry (VM) channels, migration, and invasion are the main ways for tumors to obtain nutrition. Herein, RPV-modified epirubicin and dioscin co-delivery liposomes were successfully prepared. These liposomes showed ideal physicochemical properties, enhanced tumor targeting and accumulation in tumor sites, and inhibited VM channel formation, tumor angiogenesis, migration and invasion. The liposomes also downregulated VM-related and angiogenesis-related proteins in vitro. Furthermore, when tested in vivo, the targeted co-delivery liposomes increased selective accumulation of drugs in tumor sites and showed extended stability in blood circulation. In conclusion, RPV-modified epirubicin and dioscin co-delivery liposomes showed strong antitumor efficacy in vivo and could thus be considered a promising strategy for NSCLC treatment. K E Y W O R D Sangiogenesis, cell-penetrating peptide, co-delivery liposome, non-small cell lung cancer, vasculogenic mimicry

show abstract

The efficacy of RGD modified liposomes loaded with vinorelbine plus tetrandrine in treating resistant brain glioma

Cited by 26 publications

References 36 publications

Antitumor activity of tetrandrine citrate in human glioma U87 cells in vitro and in vivo

Antitumor activity of tetrandrine citrate in human glioma U87 cells in vitro and in vivo

Nanoparticles for Stem Cell Therapy Bioengineering in Glioma

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

Contact Info

Product

Resources

About